Pentansulfonsaeure-piperidid | 14674-11-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: Pentansulfonsaeure-piperidid
• 英文别名: 1-(pentane-1-sulfonyl)-piperidine；1-Pentylsulfonylpiperidine
• CAS: 14674-11-4
• 化学式: C₁₀H₂₁NO₂S
• 分子量: 219.348
• InChiKey: CHVJWJWAMLDVPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Aryl sulfonyl piperidines
  申请人：Gillespie Paul

  公开号：US20060199816A1

  公开（公告）日：2006-09-07

  Provided herein are compounds of the formula (1): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

  本文提供了以下式（1）的化合物： 以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如II型糖尿病和代谢综合征等疾病是有用的。
• N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES
  申请人：GRIFFIOEN Gerard

  公开号：US20100197703A1

  公开（公告）日：2010-08-05

  This invention provides thiazolylpiperazine derivatives, and N-sulfonyl heterocyclic derivatives including phenyl- and benzyl-thiazolylpiperidine derivatives, and pharmaceutically acceptable salts thereof, which are useful active ingredients for administration in a method for the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides methods for making such derivatives, and pharmaceutical compositions including such derivatives together with pharmaceutically acceptable excipients.

  该发明提供了噻唑基哌嗪衍生物，以及包括苯基和苄基噻唑基哌啶衍生物的N-磺酰杂环衍生物，以及其药学上可接受的盐，这些是用于治疗α-突触核蛋白病的有效活性成分，如帕金森病、弥漫性小体病、创伤性脑损伤、肌萎缩侧索硬化症、尼曼-匹克病、哈勒沃登-施帕茨综合征、唐氏综合征、神经轴突萎缩、多系统萎缩和阿尔茨海默病的治疗方法。该发明还提供了制备这些衍生物的方法，以及包括这些衍生物和药学上可接受的辅料的药物组合物。
• Substituted amidine derivatives as inhibitors of cell adhesion
  申请人：——

  公开号：US20030092746A1

  公开（公告）日：2003-05-15

  Compounds of Formula I are antagonists of VLA-4 and/or &agr; 4 &bgr; 7 , and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

  化合物I的拮抗剂是VLA-4和/或α4β7，因此可用于抑制或预防细胞黏附和细胞黏附介导的病变。这些化合物可以制成药物组合物，适用于治疗艾滋病相关痴呆、过敏性结膜炎、过敏性鼻炎、阿尔茨海默病、哮喘、动脉粥样硬化、自体骨髓移植、某些类型的毒性和免疫性肾炎、接触性皮肤过敏、炎症性肠病包括溃疡性结肠炎和克罗恩病、炎症性肺病、病毒感染的炎症后遗症、脑膜炎、多发性硬化症、多发性骨髓瘤、心肌炎、器官移植、牛皮癣、肺纤维化、再狭窄、视网膜炎、类风湿关节炎、败血性关节炎、中风、肿瘤转移、葡萄膜炎和I型糖尿病。
• Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors
  申请人：Schering Corporation

  公开号：US20040229902A1

  公开（公告）日：2004-11-18

  In an embodiment, this invention discloses novel gamma secretase inhibitors of Formulae I: 1 wherein the various moieties are described herein. Also disclosed is a method of treating Alzheimer's disease using a compound of Formula I or a composition comprising the compound of Formula I.

  在一种实施例中，本发明揭示了具有以下结构的新型γ-分泌酶抑制剂：I:1，其中各种基团在此处描述。还公开了使用Formula I化合物或包含Formula I化合物的组合物治疗阿尔茨海默病的方法。
• ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS
  申请人：PFIZER INC.

  公开号：EP0821671A1

  公开（公告）日：1998-02-04